Mereo acquired a portfolio of three product candidates from Novartis in July 2015 including BPS-804 (setrusumab), BCT-197 (acumapimod), and BGS-649 (leflutrozole).
The company in-licensed MPH-966 (alvelestat) from AstraZeneca in October 2017.